FigureĀ 3.
sBCMA levels parallel BM plasma cell BCMA expression. sBCMA levels from peripheral blood plasma at relevant timepoints show that low plasma sBCMA reflects the loss of plasma cell BCMA expression when assessed relative to the method of disease burden measurement used for each patient. (A) Patient 1 showed undetectable sBCMA before treatment with teclistamab (Tec). (B) Patient 2 showed undetectable sBCMA while in a CR to BCMA-directed CAR T-cell therapy, which remained low following relapse. (C) Patient 3 showed a disproportionate drop in sBCMA relative to serum monoclonal protein while in a PR to belantamab mafodotin (Bela), which preceded eventual BCMA-negative relapse. CR, complete response; PC, plasma cell; PR, partial response.

sBCMA levels parallel BM plasma cell BCMA expression. sBCMA levels from peripheral blood plasma at relevant timepoints show that low plasma sBCMA reflects the loss of plasma cell BCMA expression when assessed relative to the method of disease burden measurement used for each patient. (A) Patient 1 showed undetectable sBCMA before treatment with teclistamab (Tec). (B) Patient 2 showed undetectable sBCMA while in a CR to BCMA-directed CAR T-cell therapy, which remained low following relapse. (C) Patient 3 showed a disproportionate drop in sBCMA relative to serum monoclonal protein while in a PR to belantamab mafodotin (Bela), which preceded eventual BCMA-negative relapse. CR, complete response; PC, plasma cell; PR, partial response.

or Create an Account

Close Modal
Close Modal